Abstract: Calcium reacting photoproteins are a class of self-illuminating proteins that emit light upon contact with calcium. Fluorescent Proteins are small proteins that change the color of light when excited. Fluorescent Proteins and Calcium Activated Photoproteins can be used to enhance, dazzle, amaze, startle, and otherwise entertain an audience by their direct application on to the audience, surroundings, the actors, or sprayed on settings as in the newer 4D movies. The disclosure comprises novel Coelenterazine compounds and methods of use, including a simple delivery device for the photoprotein to create unique and novel cinematic, theatrical, stage, movie and musical concert optical effects by their luminous reaction upon contact with surfaces that contain calcium. Calcium is ubiquitous in and on most surfaces and in the environment; it is this unique property of calcium that makes this a novel use of the photoproteins for entertainment. A generic formula of Coelenterazine as shown.

Abstract: The present invention provides methods for the preparation of substituted heterocycle fused gamma-carbolines, such as Formula 2J, as shown below, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines, and as further defined herein:

Abstract: The present invention provides use of Tadalafil as a protein arginine methyltransferase 5 (PRMT5) inhibitor. The present invention finds out that Tadalafil is a PRMT5 inhibitor by virtually screening active compounds targeting PRMT5 based on crystal structure and information about active sites of PRMT5. The present invention not only confirms that Tadalafil can inhibit an enzymatic activity of PRMT5, but also confirms that Tadalafil alone can inhibit tumor growth in breast cancer and improve sensitivity to chemotherapy for breast cancer.

Abstract: The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.

Abstract: The present invention provides methods for the preparation of certain optionally substituted heterocycle fused gamma-carbolines of Formula 2F, as shown below and as further defined herein:

Abstract: The present disclosure relates to an improved process for the synthesis of piperazine ring, particularly for the preparation of heterocyclic compounds useful as intermediates in the synthesis of pyrazinocarbazoles such as the antidepressant Pirlindole. The process described is useful to prepare Pirlindole enantiomers, or a pharmaceutically accepted salt thereof.

Abstract: The present invention relates to an improved process for the preparation of Pirlindole enantiomers, or a pharmaceutically acceptable salt thereof.

Abstract: This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.

Abstract: This invention is in the area of pyrimidine-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.

Abstract: This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.

Abstract: The present invention provides methods for the preparation of certain optionally substituted heterocycle fused gamma-carbolines of Formula 2J, as shown below and as further defined herein:

Abstract: The disclosure comprises novel Coelenterazine compounds and methods of use, including a simple delivery device for the photoprotein to create effects by their luminous reaction upon contact with surfaces that contain calcium. Calcium is ubiquitous in and on most surfaces and in the environment; it is this unique property of calcium that makes this a novel use of the photoproteins for entertainment. A base coelenterazine structure is depicted below.

Abstract: The present invention provides methods for the preparation of substituted heterocycle fused gamma-carbolines of Formula 2F, as shown below, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines, such methods comprising the preparation of a Compound of Formula 2F, as shown below and as further defined herein:

Abstract: Provided is a novel organic compound that is used as a host material in which a light-emitting substance is dispersed. The organic compound is represented by General Formula (G1). In the formula, A represents a substituted or unsubstituted dibenzofuran-diyl group, a substituted or unsubstituted dibenzothiophene-diyl group, a substituted or unsubstituted N-aryl-9H-carbazole-diyl group, or a substituted or unsubstituted N-alkyl-9H-carbazole-diyl group; Ar1 and Ar2 each independently represent a single-bond or a substituted or unsubstituted arylene group; R11 to R19 and R21 to R29 each independently represent hydrogen, an alkyl group having 1 to 6 carbon atoms, or a substituted or unsubstituted aryl group having 6 to 13 carbon atoms; X1 and X2 each independently represent a carbon atom or a nitrogen atom; and the carbon atom is bonded to hydrogen, an alkyl group having 1 to 6 carbon atoms, or a substituted or unsubstituted aryl group having 6 to 13 carbon atoms.

Abstract: A novel heterocyclic compound is provided. A novel heterocyclic compound that can be used for a light-emitting element is provided. A novel heterocyclic compound that can improve the reliability of a light-emitting element when used for a light-emitting element is provided. A light-emitting element, a light-emitting device, an electronic appliance, or a lighting device which includes the novel heterocyclic compound and is highly reliable is provided. One embodiment of the present invention is a heterocyclic compound represented by a general formula (G0). In the general formula (G0), A represents a dibenzo[f,h]quinoxalinyl group, B represents a substituted or unsubstituted fluorenyl group, and Ar represents a substituted or unsubstituted arylene group having 6 to 25 carbon atoms.

Abstract: The present invention provides methods for the preparation of substituted heterocycle fused gamma-carbolines of Formula 2J, as shown below, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines, such methods comprising the preparation of a Compound of Formula 2G, as shown below, and use of said compound to produce the fused gamma-carbolines of Formula 2J, as defined herein:

Abstract: The invention relates to substituted heterocycle fused gamma-carbolines of the Formula Q as described herein, in free base or pharmaceutically acceptable salt form, and/or pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor pathway, the serotonin transporter (SERT) pathway and/or the dopamine D2 receptor pathway signaling systems.

Abstract: Novel compounds in the classes of Imidazo[1,2-?]pyrazines and Imidazo[1,2-?]quinoxalines with a methoxy group modification show unique spectral properties when used as a substrate for luciferases and photo-proteins. Methoxy e-Coelenterazine an Imidazo[1,2-?] quinoxaline shifts the emission wavelength by 80 nm to blue light compared to e-Coelenterazine, using Renilla reniformis luciferase. The novel analogs described here are useful in combination with fluorescent proteins to create BRET (bioluminescent resonance energy transfer) and for other luminescent assays. In addition these novel compounds can be used in novelty items and for entertaining purposes to create different light emitting colors using the same luciferase or photoprotein.

Abstract: The present application provides, among other things, a compound of Formula I-a and/or I-b, or a pharmaceutically acceptable salt thereof, wherein the variables are defined in the specification. The compounds of the invention are useful for treating various diseases including cancer.

Abstract: The present invention provides methods for the preparation of 4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido-[3?,4?:4,5]-pyrrolo[1,2,3-de]quinoxalin-8-(7H)-yl)-1-(4-fluorophenyl)-1-butanone in free form or a salt thereof.

Abstract: The present invention relates to co-crystals of tadalafil with hydroxyl-substituted benzoic acid coformers having the following structure. Said co-crystals can be used to produce a pharmaceutical composition containing the same as the useful active ingredient. Said co-crystals can exhibit a constant storage stability.

Abstract: The present invention relates to 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone tosylate salt in crystalline and in solid forms, the method of making and using such crystals.

Abstract: The present invention provides, among other things, imidazo[1,2-?]pyrazine derivatives according for Formula (Ia) or Formula (Ib). The derivatives are useful in any method which other coelenterazines have been used. For example, the derivatives may be used in a bioluminogenic method to detect the presence of certain compounds or molecules.

Abstract: Crystalline molecular complexes of tadalafil are disclosed. The crystalline molecular complexes include those of tadalafil and oxalic acid, tadalafil and 4-hydroxybenzoic acid, tadalafil and 3-phenylpropanoic acid, tadalafil and malonic acid, tadalafil and methylparaben, and tadalafil and propylparaben. Pharmaceutical compositions containing the crystalline molecular complexes are also disclosed.

Abstract: This disclosure is directed to fused tetracyclic pyrido[4,3-b>]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

Abstract: A 6H-indolo[2,3-b]quinoxaline derivative has a structure of formula (I). R9 is a member selected from the group consisted of an aryl group having one or more substituents and a heteroaryl group having one or more substituents, and R1 to R8 are substituents. The 6H-indolo[2,3-b]quinoxaline derivative of the present invention incorporates an indole and a quinoxaline group therefore inherits good energy transfer ability from indole and good electron-injection ability from quinoxaline. The compound of the present invention may function as a host material or a dopant in the light-emitting layer. In addition, the compound of the present invention may function as hole transport material, electron transport material, hole blocking material, electron blocking material, hole injecting material or electron injecting material.

Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D2 receptor signaling systems.

Abstract: A dibenzo[f,h]quinoxaline derivative in which impurities are reduced and a novel method of synthesizing the dibenzo[f,h]quinoxaline derivative in which impurities are reduced are provided. In addition, a light-emitting element, a light-emitting device, an electronic appliance, or a lighting device with high emission efficiency and high reliability in which the dibenzo[f,h]quinoxaline derivative is used as an EL material is provided. In the synthesis method, a 2-(chloroaryl)dibenzo[f,h]quinoxaline derivative is used as a synthetic intermediate in a synthetic pathway so that an impurity contained in a final product can be removed easily by purification by sublimation.

Abstract: Provided is a heterocyclic compound that can be used for a carrier-transport material, a host material, or a light-emitting material in a light-emitting element. The heterocyclic compound has an indolo[3,2,1-jk]carbazole skeleton and a dibenzo[f,h]quinoxaline skeleton which are linked to each other through an arylene group. The wide band gap of the heterocyclic compound allows excitation of a green-emissive phosphorescent material, which contributes to the formation of a highly efficient light-emitting element.

Abstract: A novel organic compound is provided. In addition, a novel organic compound with high heat resistance is provided. In the organic compound, a dibenzoquinoxaline skeleton and a 4,4-bidibenzofuran skeleton or a 4,4?-bidibezothiophene skeleton are connected to each other through an arylene group.

Abstract: A simple process for producing v-coelenterazine compounds has been desired. Described is a process for producing a v-coelenterazine compound represented by general formula (II) comprising (1) the step of reacting a compound of general formula (VIII) with a methyltriphenylphosphonium salt in the presence of a base to give a compound represented by general formula (IX), (2) the step of performing a ring-closing metathesis reaction on any one selected from the group consisting of the compound represented by general formula (IX) and a compound of general formula (X) which is the compound of general formula (IX) wherein the amino is protected with R5, and then deprotecting R4 and, if any, R5 to give a v-coelenteramine compound represented by general formula (XIV), and (3) the step of reacting the compound of general formula (XIV) with a compound represented by general formula (XV) to give the compound of general formula (II).

Abstract: A novel heterocyclic compound that can be used as a host material in which a light-emitting substance is dispersed. A light-emitting element having a long lifetime. A heterocyclic compound in which a substituted or unsubstituted dibenzo[f,h]quinoxalinyl group is bonded to a substituted or unsubstituted arylene group having 6 to 25 carbon atoms which is bonded to any one of the 8-11 positions of a substituted or unsubstituted benzo[b]naphtho[1,2-d]furan skeleton.

Abstract: Provided is a novel organic compound that can be used as a host material of a light-emitting layer in which a light-emitting substance is dispersed. The organic compound is represented by General Formula (G1-1). In the formula, A represents a substituted or unsubstituted dibenzo[f,h]quinoxalin-yl group, Ar1 represents a substituent formed by 1 to 4 rings, and n represents 2 or 3, where the ring is a substituted or unsubstituted benzene ring or a substituted or unsubstituted fluorene ring.

Abstract: The present invention provides, among other things, imidazo[1,2-?]pyrazine derivatives according for Formula (Ia) or Formula (Ib). The derivatives are useful in any method which other coelenterazines have been used. For example, the derivatives may be used in a bioluminogenic method to detect the presence of certain compounds or molecules.

Abstract: Provided is a novel organic compound that is used as a host material in which a light-emitting substance is dispersed. The organic compound is represented by General Formula (G1). In the formula, A represents a substituted or unsubstituted dibenzofuran-diyl group, a substituted or unsubstituted dibenzothiophene-diyl group, a substituted or unsubstituted N-aryl-9H-carbazole-diyl group, or a substituted or unsubstituted N-alkyl-9H-carbazole-diyl group; Ar1 and Ar2 each independently represent a single-bond or a substituted or unsubstituted arylene group; R11 to R19 and R21 to R29 each independently represent hydrogen, an alkyl group having 1 to 6 carbon atoms, or a substituted or unsubstituted aryl group having 6 to 13 carbon atoms; X1 and X2 each independently represent a carbon atom or a nitrogen atom; and the carbon atom is bonded to hydrogen, an alkyl group having 1 to 6 carbon atoms, or a substituted or unsubstituted aryl group having 6 to 13 carbon atoms.

Abstract: Nonlinear optic chromophores comprising stabilized radical structures, mixtures thereof, methods for their production, nonlinear optical materials containing such chromophores, and the use of such materials in electro-optic, solar conversion, photovoltaic and all-optical nonlinear devices are described.

Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein L, R5, W, X, Y1, Y2, and Z are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: The present invention provides methods for the preparation of substituted heterocycle fused gamma-carbolines, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines.

Abstract: Donor-acceptor compounds with nitrogen containing polyaromatics as the acceptor with emission originated from the charge transfer (CT) state is disclosed. The donor-acceptor compound is provided that has the structure of Formula 1 shown below: wherein X1 to X12 is independently selected from the group consisting of C—R and N, wherein at least one of X1 to X12 is N, wherein each R is independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof; and at least one of the R comprises a donor group with at least two electron-donating nitrogens.

Abstract: Provided is a heterocyclic compound that can be used for a carrier-transport material, a host material, or a light-emitting material in a light-emitting element. The heterocyclic compound has an indolo[3,2,1-jk]carbazole skeleton and a dibenzo[f,h]quinoxaline skeleton which are linked to each other through an arylene group. The wide band gap of the heterocyclic compound allows excitation of a green-emissive phosphorescent material, which contributes to the formation of a highly efficient light-emitting element.

Abstract: Disclosed are an organometallic complex emitting red light with high color purity. An organometallic complex having a structure represented by the following general formula (G1) is provided. In the formula, of R1 to R13, at least one represents an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms and the other or others represent hydrogen. M represents a central metal, which is a Group 9 or Group 10 element. L represents a monoanionic ligand, and n is 2 when the central metal is a Group 9 element or 1 when the central metal is a Group 10 element.

Abstract: The present invention relates to toluenesulfonic acid addition salt crystals of specific substituted heterocycle fused gamma-carbolines, the method of making and using such crystals.

Abstract: The present invention relates to a process for the preparation of tadalafil of Formula I, comprising reacting a D-tryptophan compound of Formula III with piperonal in sulfolane.

Abstract: There is disclosed a formulation for creating a rapid penile erection within 30 minutes. In an embodiment, a lozenge has a preparation configured to create a rapid penile erection. The preparation is effective to create the rapid penile erection with sildenafil citrate in a range of 50-100 mg. The preparation is effective to create the rapid penile erection with tadalafil in a range of 5-40 mg. The preparation is effective to create the rapid penile erection with vardenafil hydrochloride in a range of 5-40 mg. In various embodiments, the formulation includes a solvent configured to permeate skin. Other embodiments are also disclosed.

Abstract: The present invention describes triphenylene derivatives, in particular for use as triplet matrix materials in organic electroluminescent devices. The invention furthermore relates to a process for the preparation of the compounds according to the invention and to electronic devices comprising same.

Abstract: The present invention relates to a novel compound having an antiviral effect, more specifically, a pyridone derivative having HIV integrase inhibitory activity, and a medicament containing the same, in particular, an anti-HIV agent. The compound of the present invention has integrase inhibitory activity and/or cell proliferation inhibitory activity against viruses, in particular, HIV and drug-resistant strains thereof. Thus, the compound is useful in preventing or treating various diseases, viral infections (for example, AIDS), and the like in which integrase participates.

Abstract: The disclosure describes compounds of formula I, wherein the wedged bonds, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, X and Y have meanings given in the description, and pharmaceutically-acceptable salts thereof; and methods of using such compounds useful in the treatment of cancer and conditions affected by inhibition of angiogenesis. Also provided, are processes for the preparation of formula I, by reacting formula I with other compounds; and processes for the preparation of a pharmaceutical formulation by bringing into association, a compound of formula I, with therapeutic agents and/or a pharmaceutically-acceptable adjuvant, diluent, or carrier.

Abstract: A compound for an organic optoelectronic device represented by Chemical Formula 1 wherein, in Chemical Formula 1, variables A, Y1 to Y4, X1, m, R1 to R4, L1 to L3, n1 to n3, Ar1 and Ar2 are described in the specification.

Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor ?2A. The compounds may also bind to and are an antagonist of the adrenergic receptor ?2B; or the compounds are not antagonists of the adrenergic receptor ?2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.